First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19

Burlingame, CA, May 6, 2020 -- Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s propri

Latest News Clinical News 1040
Read All

GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

May 6, 2020, Hong Kong -- China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce

Latest News Clinical News 743
Read All

Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE

BEIJING -- Sinovac Biotech Ltd. May 06, 2020 -- (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today the publication of the preclinica

Latest News Clinical News 942
Read All

Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

NEW YORK & MAINZ, Germany--(BUSINESS WIRE) May 5, 2020 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phas

Latest News Clinical News 675
Read All

TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia

NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from the global UNITY-CLL Phase 3 trial evaluating the combination of umbralis

Latest News Clinical News 730
Read All

Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

CAMBRIDGE, Mass., May 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann

Latest News Clinical News 716
Read All

DelMar Pharmaceuticals Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors

SAN DIEGO, May 5, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid

Latest News Clinical News 655
Read All

Relief Therapeutics Holding Drug Aviptadil Enters FDA Trial at University of California Irvine, to Treat COVID-19-Induced Acute Respiratory Distress

Geneva, Switzerland: May 4, 2020 -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” announces that the University of California, Irvine is participating in the Phase 2 clinical study of its drug Avi

Latest News Clinical News 824
Read All

GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome

SARASOTA, Fla. and NOVATO, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development

Latest News Clinical News 760
Read All

FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S.

VANCOUVER, Washington, May 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antag

Latest News Clinical News 690
Read All

Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19

SHANGHAI and INDIANAPOLIS, May 4, 2020 /PRNewswire/ -- Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeut

Latest News Clinical News 631
Read All

Gilead’s Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 1, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA)

Latest News Clinical News 686
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism